Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.81 |
| ▸ | CCR3 | P51677 | 20/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967140 | 0.93 | HRH1 (0.69) | HRH1CCR3KCNH2 | |
| SCHEMBL4967137 | 0.90 | HRH1 (0.66) | HRH1CCR3KCNH2 | |
| SCHEMBL4970161 | 0.90 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL4965086 | 0.89 | HRH1 (0.65) | HRH1CCR3KCNH2 | |
| SCHEMBL5189874 | 0.87 | HRH1 (0.81) | HRH1CCR3KCNH2 | |
| SCHEMBL4970994 | 0.86 | HRH1 (0.82) | HRH1CCR3KCNH2 | |
| SCHEMBL4966177 | 0.85 | CCR3 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL4967114 | 0.84 | HRH1 (0.83) | HRH1CCR3KCNH2 | |
| SCHEMBL3938942 | 0.84 | CCR3 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL3938940 | 0.84 | CCR3 (0.61) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
| EP-1625114-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099144-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.